FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963599260> ?p ?o ?g. }

• W1963599260 endingPage "656" @default.
• W1963599260 startingPage "646" @default.
• W1963599260 abstract "The characteristic expression of the constitutively active oncoprotein, BCR-ABL tyrosine kinase, in chronic myeloid leukemia (CML) was the basis for the development of BCR-ABL tyrosine kinase inhibitors for treatment. Three BCR-ABL inhibitors, imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP).This article reviews the key phase III clinical trials supporting the use of first-line imatinib, nilotinib, and dasatinib in patients with CML-CP, as well as findings of supportive phase II studies.At the time of its approval in 2001, imatinib induced unprecedented response rates in patients with CML-CP; however, resistance and intolerance to imatinib prevent 20% to 30% of patients from deriving full therapeutic benefit. Nilotinib and dasatinib, both approved in 2010 for first-line CML-CP treatment, are more potent than imatinib and less susceptible to imatinib resistance mechanisms. Comparative clinical trials of each agent with imatinib have shown that they are associated with significantly deeper and more rapid responses than standard-dose imatinib, without compromising safety.Given that evidence suggests achievement of an early response is predictive of improved long-term outcomes, earlier use of these compounds may lead to more rapid, deeper responses corresponding with improvements in patient outcome. Although future studies will benefit from more uniform definitions of end points and methods of analysis, data from published studies of first-line BCR-ABL inhibitor treatment for patients with newly diagnosed CML-CP support the use of dasatinib or nilotinib in place of imatinib." @default.
• W1963599260 created "2016-06-24" @default.
• W1963599260 creator A5014346242 @default.
• W1963599260 creator A5049385583 @default.
• W1963599260 date "2013-12-01" @default.
• W1963599260 modified "2023-09-23" @default.
• W1963599260 title "A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase" @default.
• W1963599260 cites W1523946531 @default.
• W1963599260 cites W1965429870 @default.
• W1963599260 cites W1968747503 @default.
• W1963599260 cites W1980571402 @default.
• W1963599260 cites W1993474153 @default.
• W1963599260 cites W1993756686 @default.
• W1963599260 cites W1994279776 @default.
• W1963599260 cites W2001335864 @default.
• W1963599260 cites W2009746825 @default.
• W1963599260 cites W2021095507 @default.
• W1963599260 cites W2021648831 @default.
• W1963599260 cites W2028959752 @default.
• W1963599260 cites W2029573515 @default.
• W1963599260 cites W2033521825 @default.
• W1963599260 cites W2036823605 @default.
• W1963599260 cites W2037878975 @default.
• W1963599260 cites W2038161969 @default.
• W1963599260 cites W2052054991 @default.
• W1963599260 cites W2057206328 @default.
• W1963599260 cites W2057827171 @default.
• W1963599260 cites W2061440903 @default.
• W1963599260 cites W2061860992 @default.
• W1963599260 cites W2068248632 @default.
• W1963599260 cites W2070507117 @default.
• W1963599260 cites W2072834954 @default.
• W1963599260 cites W2074198797 @default.
• W1963599260 cites W2074740555 @default.
• W1963599260 cites W2079517811 @default.
• W1963599260 cites W2090767358 @default.
• W1963599260 cites W2091005492 @default.
• W1963599260 cites W2095846263 @default.
• W1963599260 cites W2097799776 @default.
• W1963599260 cites W2097946794 @default.
• W1963599260 cites W2103796073 @default.
• W1963599260 cites W2105057140 @default.
• W1963599260 cites W2107268345 @default.
• W1963599260 cites W2107610389 @default.
• W1963599260 cites W2124196948 @default.
• W1963599260 cites W2143939343 @default.
• W1963599260 cites W2146658081 @default.
• W1963599260 cites W2151838891 @default.
• W1963599260 cites W2158884958 @default.
• W1963599260 cites W2168633862 @default.
• W1963599260 cites W2172189430 @default.
• W1963599260 cites W2261840157 @default.
• W1963599260 cites W2322365534 @default.
• W1963599260 cites W2550919857 @default.
• W1963599260 cites W2561124086 @default.
• W1963599260 cites W2562944591 @default.
• W1963599260 cites W2564004309 @default.
• W1963599260 cites W2593142701 @default.
• W1963599260 cites W2979821888 @default.
• W1963599260 doi "https://doi.org/10.1016/j.clml.2013.05.012" @default.
• W1963599260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4784255" @default.
• W1963599260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24095296" @default.
• W1963599260 hasPublicationYear "2013" @default.
• W1963599260 type Work @default.
• W1963599260 sameAs 1963599260 @default.
• W1963599260 citedByCount "21" @default.
• W1963599260 countsByYear W19635992602014 @default.
• W1963599260 countsByYear W19635992602015 @default.
• W1963599260 countsByYear W19635992602016 @default.
• W1963599260 countsByYear W19635992602017 @default.
• W1963599260 countsByYear W19635992602018 @default.
• W1963599260 countsByYear W19635992602019 @default.
• W1963599260 countsByYear W19635992602021 @default.
• W1963599260 countsByYear W19635992602022 @default.
• W1963599260 crossrefType "journal-article" @default.
• W1963599260 hasAuthorship W1963599260A5014346242 @default.
• W1963599260 hasAuthorship W1963599260A5049385583 @default.
• W1963599260 hasBestOaLocation W19635992602 @default.
• W1963599260 hasConcept C121608353 @default.
• W1963599260 hasConcept C126322002 @default.
• W1963599260 hasConcept C143998085 @default.
• W1963599260 hasConcept C170493617 @default.
• W1963599260 hasConcept C2777413986 @default.
• W1963599260 hasConcept C2777583451 @default.
• W1963599260 hasConcept C2778729363 @default.
• W1963599260 hasConcept C2778820342 @default.
• W1963599260 hasConcept C2779536868 @default.
• W1963599260 hasConcept C42362537 @default.
• W1963599260 hasConcept C535046627 @default.
• W1963599260 hasConcept C71924100 @default.
• W1963599260 hasConcept C98274493 @default.
• W1963599260 hasConceptScore W1963599260C121608353 @default.
• W1963599260 hasConceptScore W1963599260C126322002 @default.
• W1963599260 hasConceptScore W1963599260C143998085 @default.
• W1963599260 hasConceptScore W1963599260C170493617 @default.
• W1963599260 hasConceptScore W1963599260C2777413986 @default.
• W1963599260 hasConceptScore W1963599260C2777583451 @default.
• W1963599260 hasConceptScore W1963599260C2778729363 @default.

• next